BCAT2 and bladder transitional cell carcinoma: Inspiringly, in the aspect of survival outcome, low BCAT2 group had a longer disease‐free survival (DFS) than high BCAT2 group (p = 0.032) (Figure 7F), demonstrating the prognosis value of BCAT2 in BLCA immunotherapy.